MAPT and Alzheimer disease: Importantly, inactivation of GSK-3β through phosphorylation at Ser9 has been shown to reduce tau hyperphosphorylation and mitigate microtubule destabilization—two hallmarks of AD pathology (Medina and Avila, 2014).